OncoCyte Corporation (AMEX:OCX) changes shares on Wednesday trading session, with a change of -5.82% or -$0.11 shares. The trading starts at $1.97 and closed at $1.89 throughout the day. The trading session low price was $1.72 and day high was $2.03 on Wednesday, August 05. After the session, the Healthcare sector daily volume shifted to 1.83 million while its average volume is 981.39K. In other hand, the OCX market cap reached to $129.48M.
Checking out the performance report which defines the increase or decrease of prices for a specific period. For the last 5 trading sessions, its performance is up 29.93% and up 42.40% for month. Its quarterly performance was -30.47% below, while its half year performance is down -32.32%. OCX yearly performance stood at positive 1.71% and fall -20.89% for year-to-date. Current recommendation for OncoCyte Corporation is 2.40.
Earnings per share or EPS is an important financial measure, which defines the profitability of a company. OCX EPS (TTM) for 12-month is -0.48. EPS for this year is -5.00%, while for the next year its value is -0.33. Its EPS Q/Q reached -33.60%. It has an EPS of -17.40% down for past five years.
On the other hand, target price ranges from $1.50 – $6.00. Average target price for OCX was reached at $3.10.
Broadwood Capital, Inc., Pura Vida Investments, LLC and Blackrock Inc. are the top three holders in OncoCyte Corporation (OCX) stock. On Mar 30, 2020, Broadwood Capital, Inc. has 13.67 million shares which valued 33.48 million. On Mar 30, 2020, Pura Vida Investments, LLC owned 5.58 million shares which valued at 13.67 million. On Mar 30, 2020, Blackrock Inc. has a total of 1.57 million shares which valued at 3.84 million. In the end, Blackrock Inc. have 2.33% shares outstanding of OncoCyte Corporation (OCX) on Mar 30, 2020. The insider ownership moved to 0.10% and institutional holding shifted to 40.50%.
The company posted an EPS (TTM) of -0.48. According to the most recent quarter report on (Sep 2020), 5 analysts estimated an average EPS of -0.1, while -0.1 EPS posted a year ago period. Analyst Estimated EPS for OCX published in the report was -$0.12 – -$0.08 during the same period. Comparing with last year, the average estimated EPS was -0.1 which is higher than -0.14 which was posted for recent quarter EPS.
A brief look on simple moving average (SMA) that determines the market price can impact a market. The SMA for OCX fall -19.20% for period of 200 days. SMA for 50 days was -14.76% which is showing red signal, while SMA-20 was 28.29%. The moving average value for OncoCyte Corporation (OCX) is 2.3061 and 1.8800 for 200 and 50 days respectively.
Let’s take a look on the insider transactions, in which multiple shareholders are showing interest in OCX stock. On Aug 03, ANDREWS RONALD ASBURY, Chief Executive Officer, bought 40,000 trading shares at the cost of $1.35, which valued at 53880.0. On Aug 03, Levine Mitchell S, Chief Financial Officer, bought 10,000 shares at the cost of $1.32, with total shares of 36,579. On Aug 03, Parker Albert P, Chief Operating Officer, bought 5,000 shares at the cost of 1.33. After this transaction, Parker Albert P total shares reached to 5,000 which valued at 6648.0.